Menu

Potent Weed Linked to Psychosis

Frequent use of high-strength cannabis may increase the risk of mental health problems, according to a large-scale epidemiological study.

Mar 20, 2019
Jef Akst

ABOVE: © ISTOCK.COM, LPETTET

The strength of marijuana could be an important consideration when evaluating the health risks of using cannabis, according to a study of more than 2,000 patients and controls published yesterday (March 19) in The Lancet Psychiatry.

At 10 locations in Europe and another in Brazil, researchers found that variation in the incidence of psychotic disorder correlated with differences in the frequency of cannabis use and, in particular, the use of high-potency cannabis, which can carry levels of psychoactive tetrahydrocannabinol (THC) greater than 10 percent.

“Daily use of high-potency cannabis and how this varies across Europe explains some of the striking variations we have measured in the incidence of psychotic disorder,” coauthor Marta Di Forti of King’s College London tells The Guardian.

After controlling for education, drinking habits, and other factors, the researchers found that there was a 40 percent greater chance of developing a psychotic disorder among people who had used the drug more than once a week, as compared with those who had rarely or never tried cannabis. The risk was three times greater among daily users, as compared with rare or nonusers, and higher still among daily users of high-potency cannabis.

The link between daily use of cannabis and psychosis was strongest in Amsterdam, where cannabis is sold in coffee shops and is almost always quite potent, with varieties containing up to 67 percent THC. The researchers estimated that if high-potency versions of the drug were not available, half of first-time cases of psychotic disorders in the city could be avoided.

“If you are going to legalise cannabis, unless you want to pay for more a lot more psychiatric beds and a lot more psychiatrists, then you need to devise a system where you would legalise in a way that wouldn’t increase the consumption and increase the potency,” coauthor Robin Murray, from King’s College London, tells The Guardian.

July 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

Overcoming the Efficiency Challenge in Clinical NGS
Overcoming the Efficiency Challenge in Clinical NGS
Download this white paper to see how an ECS lab serving a network of more than 10,000 healthcare providers integrated QIAGEN Clinical Insight (QCI) Interpret to significantly reduce manual variant curation efforts and increase workflow efficiency by 80%!
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas, Inc., an emerging diagnostic company, launched a portfolio of products that can improve the accuracy of current diagnostic test results by helping laboratory professionals detect and manage biotin interference in patient samples with VeraTest Biotin and VeraPrep Biotin.
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
Scientists presented more than 30 abstracts featuring Bio-Rad’s Droplet Digital PCR (ddPCR) technology at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31–June 4.
BellBrook Labs Receives NIH Grant for the Discovery of cGAS Inhibitors to Treat Autoimmune Diseases
BellBrook Labs Receives NIH Grant for the Discovery of cGAS Inhibitors to Treat Autoimmune Diseases
The National Institute Of Allergy And Infectious Disease recently awarded BellBrook Labs a $300,000 Small Business Innovative Research (SBIR) grant to develop novel inhibitors for the target cyclic GAMP Synthase (cGAS). The grant will be used to accelerate the discovery of new treatments for autoimmune diseases by targeting the cGAS-STING pathway.